# Kraig Biocraft Laboratories, Inc.: Form 10-Q for the period ended Mar 31, 2018

- Company: [Kraig Biocraft Laboratories, Inc.](/companies/kblb.md) (CIK 1413119)
- Form: 10-Q
- Filed: 2018-05-11
- Accepted by EDGAR: May 11, 2018, 16:17 ET
- Period: 2018-03-31
- Accession: 0001654954-18-005141
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1413119/000165495418005141/KBLBQ12018-10Q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1413119/000165495418005141/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2018-01-01 to 2018-03-31 | $20.1k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2018-01-01 to 2018-03-31 | −$226.6k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2018-01-01 to 2018-03-31 | $52.4k | us-gaap:InterestExpense |
| Income tax | 3 months, 2018-01-01 to 2018-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-01-01 to 2018-03-31 | −$278.9k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-01-01 to 2018-03-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months, 2018-01-01 to 2018-03-31 | −$78.4k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2018-01-01 to 2018-03-31 | $6.3k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2018-03-31 | $48.5k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-03-31 | $94.0k | us-gaap:AssetsCurrent |
| Total assets | at 2018-03-31 | $159.9k | us-gaap:Assets |
| Current liabilities | at 2018-03-31 | $3.7m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2018-03-31 | −$3.6m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 21,555 characters.

### FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD-LOOKING INFORMATION

The following information should be read in conjunction with Kraig Biocraft Laboratories, Inc. and its subsidiaries ("we", "us", "our", or the “Company”) condensed unaudited financial statements and the notes thereto contained elsewhere in this report. Information in this Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations," and elsewhere in this Form 10-Q that does not consist of historical facts, are "forward-looking statements." Statements accompanied or qualified by, or containing words such as "may," "will," "should," "believes," "expects," "intends," "plans," "projects," "estimates," "predicts," "potential," "outlook," "forecast," "anticipates," "presume," and "assume" constitute forward-looking statements, and as such, are not a guarantee of future performance.

Forward-looking statements are subject to risks and uncertainties, certain of which are beyond our control. Actual results could differ materially from those anticipated as a result of the factors described in the “Risk Factors” and detailed in our other Securities and Exchange Commission (“SEC”) filings. Risks and uncertainties can include, among others, international, national and local general economic and market conditions: demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; raw material costs and availability; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to obtain sufficient financing to continue and expand business operations; the ability to develop technology and products; changes in technology and the development of technology and intellectual property by competitors; the ability to protect technology and develop intellectual property; and other factors referenced in this and previous filings. Consequently, investors should not place undue reliance on forward-looking statements as predictive of future results.

Because of these risks and uncertainties, the forward-looking events and circumstances discussed in this report or incorporated by reference might not transpire. Factors that cause actual results or conditions to differ from those anticipated by these and other forward-looking statements include those more fully described elsewhere in this report and in the “Risk Factors” section of our registration statement on Form S-1.

The Company disclaims any obligation to update the forward-looking statements in this report.

### Overview

Kraig Biocraft Laboratories, Inc. is a corporation organized under the laws of Wyoming on April 25, 2006. We were organized to develop high strength fibers using recombinant DNA technology, for commercial applications in both the specialty fiber and technical textile industries. Specialty fibers are engineered for specific uses that require exceptional strength, flexibility, heat resistance and/or chemical resistance. The specialty fiber market is exemplified by two synthetic fiber products: aramid fibers and ultra-high molecular weight polyethylene fiber. The technical textile industry involves products for both industrial and consumer products, such as filtration fabrics, medical textiles (e.g., sutures and artificial ligaments), safety and protective clothing and fabrics used in military and aerospace applications (e.g., high-strength composite materials).

We are using genetic engineering technologies to develop fibers with greater strength, resiliency and flexibility for use in our target markets, namely the textile, specialty fiber and technical textile industries.

The Report of Independent Registered Public Accounting Firm to our financial statements as of December 31, 2017 include an explanatory paragraph stating that our net loss from operations and net capital deficiency at December 31, 2017 raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

#### Plan of Operations

During the next twelve months, we expect to take the following steps in connection with the further development of our business and the implementation of our plan of operations:

- We plan to accelerate both our microbiology and selective breeding programs as well as providing more resources for our material testing protocols in 2018. We spent approximately $190,988 between January 2017 and September 2017 on collaborative research and development of high strength polymers at the University of Notre Dame. We are currently reviewing plans for research spending for 2018. We expect to continue funding the collaborative research and development of high strength polymers at the University of Notre Dame
- We expect to spend approximately $13,700 on collaborative research and development of high strength polymers and spider silk protein at the University of Wyoming over the next twelve months. This level of research spending at the university is also a requirement of our licensing agreement with the university.
- We will prepare to launch operations in Vietnam according to our investment and enterprise registration certificates and with a focus on scaling our production of recombinant spider silk to commercial levels.

22

- We will consider buying an established revenue producing company in a compatible business, in order to broaden our financial base and facilitate the commercialization of our products. We expect to use a combination of stock and cash for any such purchase.
- We will also actively consider pursuing collaborative research opportunities with both private and university laboratories in areas of research which overlap the company’s existing research and development. One such potential area for collaborative research which the company is considering is protein expression platforms. If our financing allows, management will give strong consideration to increasing the breadth of our research to include protein expression platform technologies.
- We plan to actively pursue collaborative research and product testing, opportunities with companies in the biotechnology, materials, textile and other industries.
- We plan to actively pursue collaborative commercialization, marketing and manufacturing opportunities with companies in the textile and material sectors for the fibers we developed and for any new polymers that we create in 2018.
- We plan to pursue additional alternative locations for the development of commercial scale production of our recombinant materials including Monster Silk® and Dragon SilkTM

### Limited Operating History

We have not previously demonstrated that we will be able to expand our business through an increased investment in our research and development efforts or commercialization efforts. We cannot guarantee that the research and development or commercialization efforts described in this filing will be successful. Our business is subject to risks inherent in growing an enterprise, including limited capital resources, risks inherent in the research and development process and possible rejection of our products in development.

If financing is not available on satisfactory terms, we may be unable to continue our operations. Equity financing will result in a dilution to existing shareholders.

### Three months ended March 31, 2018 compared to the Three Months Ended March 31, 2017

Our revenue, operating expenses, and net loss from operations for the three month period ended March 31, 2018 as compared to the three month period ended March 31, 2017, were as follows – some balances on the prior period’s combined financial statements have been reclassified to conform to the current period presentation:

|  | Quarter Ended March 31, 2018 | 2017 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| NET REVENUES | $108,629 | $- | 108,629 | 100.00% |
| OPERATING EXPENSES: |  |  |  |  |
| General and Administrative | 181,654 | 151,645 | 30,009 | 19.79% |
| Professional Fees | 17,850 | 75,987 | (58,137) | -76.51% |
| Officer's Salary | 112,676 | 110,722 | 1,954 | 1.76% |
| Rent - related party | 2,880 | 1,920 | 960 | 100.00% |
| Research and Development | 20,127 | 114,190 | (94,063) | -82.37% |
| **Total operating expenses** | 335,187 | 454,464 | (119,277) | -26.25% |
| **Loss from operations** | (226,558) | (454,464) | 227,906 | -50.15% |
| Interest expense | (52,371) | (40,147) | (12,224) | 30.45% |
| **Net Loss** | $(278,929) | $(494,611) | 215,682 | -43.61% |

Net Revenues: During the three months ended March 31, 2018, we realized $108,629 of revenues from our business. During the three months ended March 31, 2017, we realized $0 of revenues from our business. The change in revenues between the quarter ended March 31, 2018 and 2017 was $108,629 or 100%.

Cost of Revenues: Costs of revenues for the three months ended March 31, 2018 were $0, as compared to $0 for the three months ended March 31, 2017, a change of $0 or 0%.

Gross Profit: During the three months ended March 31, 2018, we realized a gross profit of $0, as compared to $0 for the three months ended March 31, 2017, a change of $0 or 0%.

Research and development expenses: During the three months ended March 31, 2018 we incurred $20,127 research and development expenses. During the three months ended March 31, 2017 we incurred $114,190 of research and development expenses, a decrease of $94,063 or 82.37 % compared with the same period in 2018. This decrease is attributable to insourcing research efforts and reduced materials purchases.

Professional Fees: During the three months ended March 31, 2018, we incurred $17,850 professional expenses, which decreased by $58,137 or (76.51%) from $75,987 for the three months ended March 31, 2017. This decrease is attirbutable to a decrease in outside legal feel for patent filings.

Officers Salary: During the three months ended March 31, 2018, officers’ salary expenses increased to $112,676 or 1.76% from $110,722 for the three months ended March 31, 2017. The increase in officer’s salary expenses was attributable to an increase in officer’s salary.

General and Administrative Expense: General and administrative expenses increased by $30,009 or 19.79% to $181,654 for the three months ended March 31, 2018 from $151,645 for the three months ended March 31, 2017. Our general and administrative expenses for the three months ended March 31, 2018 consisted of consulting fees of $3,688 and other general and administrative expenses (which includes expenses such as Auto, Business Development, SEC Filing, Investor Relations, General Office, warrant Compensation) of $148,149, Travel of $818 and office salary of $28,999, for a total of $181,654. General and administrative expenses increased by $33,778 or 28.66% to $151,645 for the three months ended March 31, 2017 from $117,867 for the three months ended March 31, 2016. Our general and administrative expenses for the three months ended March 31, 2017 consisted of consulting fees of $48,712 and other general and administrative expenses (which includes expenses such as Auto, Business Development, SEC Filing, Investor Relations, General Office, warrant Compensation) of $78,798, Travel of $19,307 and office salary of $4,828, for a total of $151,645.

Rent – Related Party: During the three months ended March 31, 2018, rent- related party expense increased to $2,880 or 50% from $1,920 for the three months ended March 31, 2017. The increase in rent-related party expense was attributable to the signing on January 23, 2017 an 8 year property lease with the Company’s President.

Interest Expense: Interest expense increased by $12,224 to $52,371 for the three month period ended March 31, 2018 from $40,147 for the three month period ended March 31, 2017. The increase was primarily due to interest on the loans.

Net Loss: Net loss decreased by $215,682, or 43.61%, to a net loss of $278,929 for the three month period ended March 31, 2018 from a net loss of $494,611 for the three month period ended March 31, 2017. This decrease in net loss was driven primarily by decreases in professional fees and research and development expenses.

### Liquidity, Capital Resources, and Management Plans

Our condensed financial statements have been presented on the basis that we are a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As presented in the financial statements, we incurred a net loss of $278,929 during the three months ended March 31, 2018, and losses are expected to continue in the near term. The accumulated deficit is $25,998,008 at March 31, 2018. Refer to Note 5 for our discussion of stockholder deficit. We have been funding our operations through private loans and the sale of common stock in private placement transactions. Refer to Note 4 and Note 5 in the condensed financial statements for our discussion of notes payable and shares issued, respectively. Our cash resources are insufficient to meet our planned business objectives without additional financing. These and other factors raise substantial doubt about our ability to continue as a going concern. Other factors include, without limitation, risks associated with the commercialization and production of a new and unique product. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of our company to continue as a going concern.

Management anticipates that significant additional expenditures will be necessary to develop and expand our business before significant positive operating cash flows can be achieved. Our ability to continue as a going concern is dependent upon our ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations. At March 31, 2018, we had $48,523 of cash on hand. These funds are insufficient to complete our business plan and as a consequence, we will need to seek additional funds, primarily through the issuance of debt or equity securities for cash to operate our business. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to us. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stock holders, in case or equity financing.

Management has undertaken steps as part of a plan to improve operations with the goal of sustaining our operations for the next twelve months and beyond. These steps include (a) raising additional capital and/or obtaining financing; (b) controlling overhead and expenses; and (c) executing material sales or research contracts. There can be no assurance that the Company can successfully accomplish these steps and it is uncertain that the Company will achieve a profitable level of operations and obtain additional financing. There can be no assurance that any additional financing will be available to the Company on satisfactory terms and conditions, if at all. As of the date of this Report, we have not entered into any formal agreements regarding the above.

In the event the Company is unable to continue as a going concern, the Company may elect or be required to seek protection from its creditors by filing a voluntary petition in bankruptcy or may be subject to an involuntary petition in bankruptcy. To date, management has not considered this alternative, nor does management view it as a likely occurrence.

Presently, due to the lack of revenues and profitability we are not able to meet our operating and capital expenses. The success of our ability to continue as a going concern is dependent upon raising additional capital and/or financing, of which there can be no guarantee, and maintaining a break even or profitable level of operations. We have incurred operating losses since inception, and this is likely to continue in the near future.

The financial requirements of our Company will be dependent upon the financial support through credit facilities and additional sales of our equity securities. There can be no assurance, however, that such financing will be available or, if it is available, that we will be able to structure such financing on terms acceptable to us and that it will be sufficient to fund our cash requirements until we can reach a level of profitable operations and positive cash flows. If we are unable to obtain the financing necessary to support our operations, we may be unable to continue as a going concern. We currently have no firm commitments for any additional capital.

The downturn in the United States stock and debt markets could make it more difficult to obtain financing through the issuance of equity or debt securities. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses, fail to collect significant amounts owed to us, or experience unexpected cash requirements that would force us to seek alternative financing. Further, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our shares of common stock or the debt securities may cause us to be subject to restrictive covenants. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses, fail to collect significant amounts owed to us, or experience unexpected cash requirements that would force us to seek additional financing. If additional financing is not available or is not available on acceptable terms, we will have to curtail our operations.

Cash, total current assets, total assets, total current liabilities and total liabilities as of March 31, 2018 as compared to December 31, 2017, were as follows:

|  | March 31, 2018 | December 31, 2017 |
| --- | ---: | ---: |
| Cash | $48,523 | $18,150 |
| Accounts receivable | $40,993 | $25,872 |
| Prepaid expenses | $4,665 | $4,465 |
| Total current assets | $93,981 | $48,487 |
| Total assets | $159,852 | $114,499 |
| Total current liabilities | $3,739,870 | $3,490,305 |
| Total liabilities | $3,739,870 | $3,490,305 |

As of March 31, 2018, we had a working capital deficit of $3,645,889, compared to a working capital deficit of $3,441,818 at December 31, 2017. Current liabilities increased to $3,739,870 at March 31, 2018 from $3,490,305 at December 31, 2017, primarily as a result of accounts payable and accrued compensation.

For the three months ended March 31, 2018, net cash used in operations of $78,372 was the result of a net loss of $278,929 offset by depreciation expense of $6,396, warrants issued to related parties of $0, warrants issued to consultants of $72,575, change in prepaid expenses of $0, increase in accounts receivable of $15,121, an increase of accrued expenses and other payables-related party of $149,413 and a decrease in accounts payable of $14,848. For the three months ended March 31, 2017, net cash used in operations of $193,616 was the result of a net loss of $494,611 offset by depreciation expense of $4,275, warrants issued to related parties of $5,161, warrants issued to consultants of $17,472, decrease in prepaid expenses of $537, decrease in accounts receivable of $31,858, an increase of accrued expenses and other payables-related party of $137,601 and an increase in accounts payable of $104,091.

Our investing activities were $6,255 and $1,387 for the three months ended March 31, 2018 and March 31, 2017, respectively. Our investing activities for the three months ended March 31, 2018 and March 31, 2017 are attributable to purchases of fixed assets.

Our financing activities resulted in a cash inflow of $115,000 for the three months ended March 31, 2018, which is represented by $115,000 proceeds from note payable – related party. Our financing activities resulted in cash inflow of $150,000 for the three months ended March 31, 2017, which is represented by $150,000 proceeds from issuance of common stock.

### Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

### Critical Accounting Policies and Estimates

Please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the year ended December 31, 2017, for disclosures regarding the Company's critical accounting policies and estimates, as well as updates further disclosed in our interim financial statements as described in this Form 10-Q.

## Controls and procedures

As filed, 3,184 characters.

#### Evaluation of Disclosure Controls and Procedures

As of the end of our fiscal quarter ended March 31, 2018, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon those evaluations, management concluded that our disclosure controls and procedures were not effective as of March 31, 2018, to cause the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods prescribed by SEC, and that such information is accumulated and communicated to management, including our chief executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Going forward from this filing, the Company intends to work on re-establishing and maintaining disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to be effective in providing reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure.

In designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute assurance of achieving the desired objectives. Also, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. The design of any system of controls is based, in part, upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

#### Changes in Internal Control over Financial Reporting

During the quarter covered by this Report, there were no changes in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting. No remediation has been made in this quarter since, as we stated in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, we have not yet commercialized a recombinant fiber and, therefore do not yet have sufficient cash flow to carry out our remediation plans.

## Risk factors

As filed, 304 characters.

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, are not required to provide the information under this item. Please refer to Amendment No. 5 to our Registration Statement on Form S-1 filed with the SEC on May 15, 2015 under *Risk Factors.*

Filed May 11, 2018.
Source: SEC EDGAR, the filing index for accession 0001654954-18-005141. Last ingested by Listed: Oct 24, 2026, 15:09 ET. No prices; not investment advice.
